isis pharmaceuticals inc
(ISIS:Consolidated Issue Listed on NASDAQ Global Select )
C. Frank Bennett BSc, Ph.D.
Senior Vice President of Research, Isis Pharmaceuticals, Inc.
|Age||Total Calculated Compensation||This person is connected to 0 board members in 0 different organizations across 3 different industries.|
As of Fiscal Year 2012
Dr. C. Frank Bennett, BSc, Ph.D. serves as Senior Vice President of Research for Isis Pharmaceuticals, Inc. Dr. Bennett served as Senior Vice President of Antisense Research of Isis Pharmaceuticals, Inc. since January 2006. Dr. Bennett is one of the founding members of Isis. He is involved in the development of antisense oligonucleotides as therapeutic agents, including research on the application of oligonucleotides for inflammatory and cancer targets, oligonucleotide ...
2855 Gazelle CourtPhone: 760-931-9200
Carlsbad, California 92010
Board Members Memberships*
Former Director and Member of the Scientific Advisory Board
Baylor College of Medicine
University of New Mexico
|George W. Hebard III, M.B.A||Interim Principal Executive Officer, Principal Financial Officer and Interim Chief Operating Officer|
Enzon Pharmaceuticals Inc.
|Christopher Nishan Garabedian||Chief Executive Officer, President and Director|
Sarepta Therapeutics, Inc.
|John M. Maraganore Ph.D.||Chief Executive Officer and Executive Director|
Alnylam Pharmaceuticals, Inc.
|Mark J. Murray Ph.D.||Chief Executive Officer, President and Director|
Tekmira Pharmaceuticals Corporation
|Kleanthis G. Xanthopoulos Ph.D.||Chief Executive Officer, President, Principal Financial & Accounting Officer and Director|
Regulus Therapeutics Inc.
|$515.5K||Compensation as of Fiscal Year 2012.|